• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

SM-164

CAS No. 957135-43-2

SM-164 ( —— )

产品货号. M22507 CAS No. 957135-43-2

SM-164 与包含 BIR2 和 BIR3 结构域的 XIAP 蛋白结合 (IC50: 1.39 nM)。它是 XIAP 的极强拮抗剂。 SM-164 与 XIAP 的结合效力分别比其单价对应物和天然 Smac AVPI 肽强 300 倍和 7000 倍。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
2MG ¥1401 有现货
5MG ¥2341 有现货
10MG ¥3588 有现货
25MG ¥5816 有现货
50MG ¥8068 有现货
100MG 获取报价 有现货
200MG 获取报价 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    SM-164
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    SM-164 与包含 BIR2 和 BIR3 结构域的 XIAP 蛋白结合 (IC50: 1.39 nM)。它是 XIAP 的极强拮抗剂。 SM-164 与 XIAP 的结合效力分别比其单价对应物和天然 Smac AVPI 肽强 300 倍和 7000 倍。
  • 产品描述
    SM-164 binds to XIAP protein containing both the BIR2 and BIR3 domains (IC50: 1.39 nM). It acts as an extremely potent antagonist of XIAP. SM-164 binds to XIAP being 300 and 7000-times more potent than its monovalent counterparts and the natural Smac AVPI peptide, respectively. The binding affinities of SM-164 to XIAP, cIAP-1, and cIAP-2 proteins are determined using fluorescence-polarization based assays. SM-164 concurrently interacts with both BIR domains in XIAP and functions as an ultra-potent antagonist of XIAP in both cell-free functional and cell-based assays. SM-164 targets cellular XIAP and effectively induces apoptosis at concentrations as low as 1 nM in leukemia cancer cells while having minimal toxicity to normal human primary cells at 10,000 nM. SM-164 has a Ki value of 0.56 nM to XIAP protein containing both BIR2 and BIR3 domains. SM-164 has a Ki value of 0.31 nM to a cIAP-1 protein containing both BIR2 and BIR3 domains. SM-164 binds to cIAP-2 BIR3 protein with Ki values of 1.1 nM.SM-164 is highly effective in the inhibition of tumor growth and capable of achieving tumor regression in the MDA-MB-231 xenograft model. SM-164 (1 mg/kg) treatment fully inhibits tumor growth during the treatment. SM-164 (5 mg/kg) treatment reduces the tumor volume from 147±54 mm3 at the beginning of the treatment (day 25) to 54±32 mm3 at the end of the treatment (day 36), a reduction of 65%. The strong antitumor activity by SM-164 is long-lasting and not transient. SM-164 (5 mg/kg) is statistically more effective than Taxotere at the end of the treatment (P<0.01) or when the tumor size in the control group reached 750 mm3 (P<0.02).
  • 体外实验
    ——
  • 体内实验
    ——
  • 同义词
    ——
  • 通路
    Apoptosis
  • 靶点
    IAP
  • 受体
    XIAP|cIAP-1|XIAP|cIAP-2|cIAP
  • 研究领域
    ——
  • 适应症
    ——

化学信息

  • CAS Number
    957135-43-2
  • 分子量
    1121.42
  • 分子式
    C62H84N14O6
  • 纯度
    >98% (HPLC)
  • 溶解度
    DMSO:5.2 mg/mL (4.64 mM; Need ultrasonic)
  • SMILES
    [H][C@]12CC[C@H](N1C(=O)[C@H](CCCC2)NC(=O)[C@H](C)NC)C(=O)N[C@H](c1cn(CCCCc2ccc(CCCCn3cc(nn3)[C@@H](NC(=O)[C@@H]3CC[C@]4([H])CCCC[C@H](NC(=O)[C@H](C)NC)C(=O)N34)c3ccccc3)cc2)nn1)c1ccccc1
  • 化学全称
    ——

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1. Sun H, et al. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J Am Chem Soc. 2007 Dec 12;129(49):15279-94.
产品手册
关联产品
  • MX107

    MX107是一种新型有效的生存素抑制剂,有效抑制MDA-MB-231细胞增殖,IC50为3.1 uM。

  • ASTX660 mesylate

    ASTX660 mesylate 是一种新型强效 IAP 拮抗剂,靶向 cIAP1/2 和 XIAP 的 BIR3 结构域,IC50 为 12 nM 和 <40 nM。

  • LCL161

    LCL161 是一种 SMAC 模拟物,可有效结合并抑制多种 IAP(即 XIAP、c-IAP)。